InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies
Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology drug developer, announced the launch of a new AI-powered module within its RADR(R) platform to predict the efficacy of combination therapies involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis). Backed by a peer-reviewed analysis of 221 clinical trials, the tool enables precise, biomarker-guided design of cancer treatment regimens, reducing development time and cost by up to…